antisecretory drugs
Recently Published Documents


TOTAL DOCUMENTS

76
(FIVE YEARS 1)

H-INDEX

17
(FIVE YEARS 0)

2018 ◽  
Vol 90 (12) ◽  
pp. 133-139 ◽  
Author(s):  
D S Bordin ◽  
I N Voynovan ◽  
S V Kolbasnikov ◽  
Yu V Embutnieks

Diagnostic tests used to detection Helicobacter pylori are divided into invasive (requiring endoscopy) and non-invasive, direct (bacteriological, histological or molecular detection of the bacterium) and indirect (detection of urease activity of the bacterium or antibodies to it). The choice of the test is determined by the clinical situation, as well as by its availability and cost. The sensitivity of most tests is affected by the use of antisecretory drugs and antibiotics.


2018 ◽  
Vol 21 ◽  
pp. S147
Author(s):  
L. Iakovlieva ◽  
O. Gerasymova ◽  
N. Bezditko ◽  
O. Tkachova ◽  
O. Berdnik ◽  
...  

2015 ◽  
Vol 4 (2) ◽  
pp. 293-297 ◽  
Author(s):  
FUMIAKI KITAZAWA ◽  
YOKO KADO ◽  
KUMI UEDA ◽  
TAKATOSHI KOKUFU ◽  
SHIN-ICHI FUCHIDA ◽  
...  

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Jon Eik Zwisler ◽  
Dorte Ejg Jarbøl ◽  
Annmarie Touborg Lassen ◽  
Jakob Kragstrup ◽  
Niels Thorsgaard ◽  
...  

Objective. To investigate whether patients on long-term antisecretory medication need to continue treatment to control symptoms. Methods. A double-blinded randomised placebo-controlled trial in general practices in Denmark. Patients aged 18–90 who were treated with antisecretory drugs on a long-term basis were randomized to esomeprazole 40 mg or identical placebo. Outcome measures were time to discontinuation with trial medication due to failed symptom control analysed as survival data. The proportion of patients stopping trial medication during the one-year follow-up was estimated. Results. A total of 171 patients were included with a median prior duration of antisecretory treatment of four years (range: 0.5 to 14.6 years). 86 patients received esomeprazole 40 mg and 85 patients received placebo. At 12 months, statistically significantly more patients in the placebo group had discontinued (73% (62/85)) compared with the esomeprazole group (21% (18/86); p < 0.001). Conclusions. Long-term users of antisecretory drugs showed a preference for the active drug compared to placebo. However, 27% of patients continued on placebo throughout the study and did not need to reinstitute usual treatment. One in five patients treated with esomeprazole discontinued trial medication due to unsatisfactory symptom control. Discontinuation of antisecretory treatment should be considered in long-term users of antisecretory drugs. This trial is registered with Trial registration ClinicalTrials.gov ID: NCT00120315.


2014 ◽  
Vol 12 (2) ◽  
pp. 204-209 ◽  
Author(s):  
Jay R. Thiagarajah ◽  
Eun–A Ko ◽  
Lukmanee Tradtrantip ◽  
Mark Donowitz ◽  
A.S. Verkman

2013 ◽  
Vol 4 ◽  
pp. S180
Author(s):  
B. Montero-Errasquín ◽  
M.E. Baeza-Monedero ◽  
L. García-Cabrera ◽  
N. Pérez-Abascal ◽  
C. Sánchez-Casellano ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document